Please enter exact key words
Therapeutic antibody against Frizzled 4

for the Treatment of Retinopathy and Cancers

Home / Available Projects / Therapeutic antibody against Frizzled 4

Therapeutic antibody against Frizzled 4

Drug Name GPCR-targeted Project 018

Frizzled 4 (FZD4) belongs to the frizzled receptors family. It is a receptor for Wnt proteins, which can activate both Wnt/β-catenin canonical and Wnt/Ca2+ non canonical pathways. FZD4 plays an important role in retinal vascularization by binding Norrin ligand, a Wnt-unrelated growth factor, and activating the β-catenin signaling pathway. In addition, dysregulation of FZD4 expression has been reported in different type of cancers.
A monoclonal antibody specifically binding to FZD4 with high affinity is being developed. Preclinical development for familial exudative vitreoretinopathy (FEVR) and cancers is ongoing.

Target Frizzled 4 (FZD4)
Drug Modality Monoclonal antibody
Indication Familial exudative vitreoretinopathy; Cancers
Product Category Biologic
Mechanism of Action Frizzled 4 modulators
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.